Latest market price
12.13
+0.02+0.17%
OverviewShort InterestFilings
AMRNQT39Amarin Corporation plc·NASDAQ
12.13+0.17%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
OGN-0.14%$13.82GRFS+5.06%$8.51BIIB-1.82%$249.01GSK-0.77%$49.13SNY+2.73%$45.55BMY+0.86%$63.02PFE+0.49%$30.67NVO+1.13%$40.45
Snapshot
Index—P/E—EPS (ttm)-1.05Insider Own—Shs Outstand20.68MPerf Week0.33%
Market Cap250.88MForward P/E—EPS next Y-0.63Insider Trans0.00%Shs Float20.89MPerf Month-1.78%
Enterprise Value96.00MPEG—EPS next Q-0.04Short Float2.55%Perf Quarter-15.76%
Income-20.00MP/S1.43EPS this Y—Short Ratio8.07Perf Half Y-14.82%
Sales176.00MP/B0.57EPS next Y—ROA-3.02%Short Interest532.66KPerf YTD-13.11%
Book/sh21.47P/C0.78EPS next 5Y—ROE-4.26%52W High17.31 -29.92%Perf Year-26.04%
Cash/sh15.62P/FCF3.58EPS past 3/5Y—ROIC-5.36%52W Low11.25 7.82%Perf 3Y-12.55%
Dividend Est.—EV/EBITDA—Sales past 3/5Y-16.61% -19.01%Gross Margin41.17%Volatility4.59% 3.38%Perf 5Y-87.26%
Dividend TTM—EV/Sales0.55EPS Y/Y TTM—Oper. Margin-14.19%ATR (14)0.45Perf 10Y-81.05%
Dividend Ex-Date—Quick Ratio2.59Sales Y/Y TTM-22.47%Profit Margin-11.04%RSI (14)47.02Recom2.94
Dividend Gr. 3/5Y—Current Ratio3.50EPS Q/Q—SMA202.19%Beta0.76Target Price2.17
Payout0.00%Debt/Eq0.01Sales Q/Q-20.00%SMA50-6.18%Rel Volume1.46Prev Close12.11
Employees80LT Debt/Eq0.01EarningsFeb 24SMA200-15.17%Avg Volume68.80KPrice12.13
IPO DateApr 01, 1993Option/ShortYes / YesEPS/Sales Surpr.182.32% -9.63%Net Debt/EBITDA—Volume100,108Change0.17%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-25-23DowngradeJefferiesBuy → Hold
Jan-06-23UpgradeJefferiesHold → Buy$3.00
May-24-22ReiteratedGoldman SachsSell$1.50
May-06-22DowngradeJP MorganNeutral → Underweight
May-05-22DowngradeHC Wainwright & Co.Buy → Neutral
May-05-22DowngradeSVB LeerinkOutperform → Market Perform
May-05-22ReiteratedNorthland Securities$2.00
May-12-21DowngradeGoldman SachsNeutral → Sell
Mar-31-20UpgradeOppenheimerUnderperform → Perform
Mar-31-20DowngradeGoldman SachsBuy → Neutral
Latest News· Times ET
Oct-29-26
Oct-29-2601:36PM
Amarin's Q3 Earnings Beat Estimates, Revenues Miss Markzacks.com
Oct-28-26
Oct-28-2609:30PM
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcriptseekingalpha.com
10:08AM
What Amarin (AMRN) Said on Its Q3 Earnings Callmarketbeat.com
07:00AM
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Incomeglobenewswire.com
04:35AM
Amarin Corp Q3 2026 Earnings Call TranscriptBenzinga
Oct-25-26
Oct-25-2608:11AM
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)globenewswire.com
Oct-21-26
Oct-21-2608:00AM
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026globenewswire.com
Oct-14-26
Oct-14-2612:38PM
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia LabelYahoo
Oct-07-26
Oct-07-2611:08AM
ETON Stock Surges 108% in Six Months: Here's What You Need to KnowYahoo
Oct-01-26
Oct-01-2608:55AM
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa StudyYahoo
Sep-30-26
Sep-30-2602:58AM
Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX)defenseworld.net
Sep-29-26
Sep-29-2607:50AM
Teva's Branded Drugs Take Center Stage in Its Growth StrategyYahoo
Sep-19-26
Sep-19-2603:57AM
Analyzing Amarin (NASDAQ:AMRN) & Elanco Animal Health (NYSE:ELAN)defenseworld.net
Sep-16-26
Sep-16-2610:56AM
RCKT Aligns With FDA on Completing Phase II Study in Danon DiseaseYahoo
Sep-10-26
Sep-10-2611:30AM
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?Yahoo
Company

Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue176214229307—————
Cost of Goods Sold Incl. D&A10493147141—————
Gross Profit7112181166—————
Selling, General and Administrative Excl. Other77115152200—————
Research and Development19202122—————
Other Operating Expense
1000—————
Operating Income-24-14-92-57—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)7-22153—————
Net Income Before Taxes-18-36-77-54—————
Income Taxes2355—————
Consolidated Net Income-20-39-82-59—————
Net Income From Continuing Operations-20-39-82-59—————
Net Income-20-39-82-59—————
EPS (Recurring)-1.05-1.80-4.00-3.00—————
EPS (Basic, Before Extraordinaries)-1.05-1.80-4.00-3.00—————
EPS (Diluted)-1.05-1.80-4.00-3.00—————
EBITDA-17-33-74-51—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio1.451.370.891.13—————
Gross Margin40.3456.5435.3754.07—————
Operating Margin-13.64-6.54-40.17-18.57—————
Net Margin-11.36-18.22-35.81-19.22—————
Shares Outstanding21212120—————
Market Capitalization255293204348—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$21.59$18.69$15.79$12.88$9.98● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Fishman Peter L.SVP, CFOAug 01 '26Option Exercise0.0031307,774Aug 03
Ketchum Steven BEVP, Chief Scientific OfficerJul 01 '26Option Exercise0.003,688044,567Jul 15
Provoost JonathanEVP, Chief Legal OfficerJul 01 '26Option Exercise0.003,68805,888Jul 15
Keenan David PaulEVP, Chief Operating OfficerJul 01 '26Option Exercise0.003,688015,396Jul 15
Fishman Peter L.SVP, CFOJul 01 '26Option Exercise0.002,44708,667Jul 15
Berg AaronPresident and CEOJun 26 '26Option Exercise0.0012,500088,845Jun 30
Bonfiglio Patrice EadonDirectorApr 18 '26Option Exercise0.001,67601,239Apr 22
Cohen PaulDirectorApr 18 '26Option Exercise0.001,67601,239Apr 21
Sterling Louis IIIDirectorApr 18 '26Option Exercise0.001,67604,452Apr 21
Odysseas Kostas DDirectorApr 18 '26Option Exercise0.001,67601,239Apr 21
Sullivan Diane E.DirectorApr 18 '26Option Exercise0.001,67601,239Apr 21
Horn KeithDirectorApr 18 '26Option Exercise0.001,67601,239Apr 21
O'Connor OliverDirectorApr 18 '26Option Exercise0.001,67601,239Apr 21
Fishman Peter L.SVP, CFOApr 01 '26Option Exercise0.0025006,282Apr 02
Ketchum Steven BEVP, Chief Scientific OfficerJan 31 '26Option Exercise0.008,358041,941Feb 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.